Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.

Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.

Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery.

The invention relates to a hydrogenated glucose polymer composition having a total fibre content of more than 50% as determined by the AOAC 2001.03 method, and a dry weight reducing sugar content, SR, lower than 800 ppm. The invention also relates to a method for producing said composition. The invention is also directed to a food or pharmaceutical product comprising said composition.

The invention relates to a hydrogenated glucose polymer composition having a total fibre content of more than 50% as determined by the AOAC 2001.03 method, and a dry weight reducing sugar content, SR, lower than 800 ppm. The invention also relates to a method for producing said composition. The invention is also directed to a food or pharmaceutical product comprising said composition.

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.

The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.

The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.

A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.